Rosen Quoted on FDA Warning Letters Issued to Drug Compounders

31 January 2014 Inside Health Policy News

Inside Health Policy

Partner David Rosen was quoted in an Inside Health Policy article on January 31, 2014 titled, “First DQSA Warning Letters Target Compounders Without Prescriptions.” The article discusses the two warning letters issued by the FDA to drug compounders in recent weeks chastising them for lacking patient-specific prescriptions. Rosen was quoted saying, “If you do not have an individual prescription for every patient for whom you compound, this is one way FDA is sending the message that you are not compliant with 503A at this time.”

Related Services

Insights

California Statute Offers Dramatic Change to Independent Contractor, Franchise-Franchisee Relationships
20 September 2019
Legal News: Distribution & Franchise
AI Ouch! AI Job Interview Law Starting in 2020!
20 September 2019
Internet, IT & e-Discovery Blog
RCE PTA Carve-Out Resumes After Interference
18 September 2019
PharmaPatents
The Ninth Circuit Expected to Rule that Doctors Can Be Wrong in the Winter v. Gardens False Claims Act Case
18 September 2019
Legal News: Government Enforcement Defense & Investigations
Lacktman, Ferrante Cited in mHealth Intelligence About Ryan Haight Act
19 September 2019
mHealth Intelligence
Vernaglia Comments on AHA v Azar Decision
18 September 2019
MedPage Today
Tinnen Discusses How Viewpoint Diversity Helps Businesses Thrive
18 September 2019
InsideTrack
Lach Comments on Launch of New Group
16 September 2019
BizTimes Milwaukee
MedTech Impact Expo & Conference
13-15 December 2019
Las Vegas, NV
Review of 2020 Medicare Changes for Telehealth
11 December 2019
Member Call
BRG Healthcare Leadership Conference
06 December 2019
Washington, D.C.
CTeL Telehealth Fall Summit 2019
04-06 December 2019
Washington, D.C.